EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Trypanosoma cruzi Potential of New Pyrazole-Imidazoline Derivatives

Edinaldo Castro de Oliveira iD, Leonardo da Silva Lara iD, Lorraine Martins Rocha Orlando iD, Sarah da Costa Lanera, Thamyris Perez de Souza, Nathalia da Silva Figueiredo, Vitoria Barbosa Paes, Ana Carolina Mazzochi, Pedro Henrique Myra Fernandes, Maurício Silva Dos Santos iD, Mirian Claudia de Souza Pereira iD

Molecules · 2025

DOI: 10.3390/molecules30153082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Edinaldo Castro de Oliveira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Av. Brasil 4365 Manguinhos, Rio de Janeiro 21040-900, RJ, Brazil. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Pyrazoles, Trypanocidal Agents, Imidazolines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease, caused by Trypanosoma cruzi, poses a significant public health challenge due to its widespread prevalence, limited therapeutic options, and adverse effects associated with available medications. In this study, we developed 13 novel pyrazole-imidazoline derivatives, inspired by a previously identified cysteine protease inhibitor, and evaluated their antiparasitic activity. Our in silico analyses predicted favorable physicochemical profiles and promising oral bioavailability for these derivatives. Upon phenotypic screening, we observed that these new derivatives exhibited low cytotoxicity (CC50 > 100 µM) and marked efficacy against intracellular amastigotes. Derivative 1k showed high activity (IC50 = 3.3 ± 0.2 µM), selectivity (SI = 73.9), and potency (pIC50 = 5.4). In a 3D cardiac microtissue model, 1k significantly reduced parasite load, matching the efficacy of benznidazole (Bz) even at lower concentrations. Both 1k and Bz effectively prevented parasite recrudescence; however, neither resulted in parasite sterility under the experimental conditions employed. The combination of 1k–Bz yielded an additive interaction, highlighting its potential for in vivo combination therapy. While structural changes abolished cysteine protease inhibition, incorporating a CF3 substituent at the para position and excluding the amino group enhanced antiparasitic activity. These findings reinforce the promise of the pyrazole-imidazoline scaffold and support further structural optimizations to develop innovative candidates for treating Chagas disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma cruziPyrazolesTrypanocidal AgentsImidazolinesAnimalsChagas DiseaseHumansStructure-Activity Relationship

Stichwörter der Autor:innen

3D culture modelChagas diseaseTrypanosoma cruzichemotherapypyrazole-imidazoline

Substanzen

PyrazolesTrypanocidal AgentsImidazolinespyrazole

Autor:innen und Institutionen

  • Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Av. Brasil 4365 Manguinhos, Rio de Janeiro 21040-900, RJ, Brazil.
  • Laboratório de Síntese de Sistemas Heterocíclicos (LaSSH), Instituto de Física e Química (IFQ), Universidade Federal de Itajubá, Avenida BPS, 1303, Pinheirinho, Itajubá, Minas Gerais 37500-903, MG, Brazil.

ORCID-Profile: Edinaldo Castro de Oliveira, Leonardo da Silva Lara, Lorraine Martins Rocha Orlando, Maurício Silva Dos Santos, Mirian Claudia de Souza Pereira

Förderung

  • National Council for Scientific and Technological Development
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Fundação Oswaldo Cruz, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
  • Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Physics and Chemistry Institute-UNIFEI

Zitieren

APA

de Oliveira, E. C., Lara, L. D. S., Orlando, L. M. R., Lanera, S. D. C., de Souza, T. P., Figueiredo, N. D. S., Paes, V. B., Mazzochi, A. C., Fernandes, P. H. M., Dos Santos, M. S., & Pereira, M. C. S. (2025). Anti-Trypanosoma cruzi Potential of New Pyrazole-Imidazoline Derivatives. Molecules. https://doi.org/10.3390/molecules30153082

Vancouver

de Oliveira EC, Lara LDS, Orlando LMR, Lanera SDC, de Souza TP, Figueiredo NDS, et al. Anti-Trypanosoma cruzi Potential of New Pyrazole-Imidazoline Derivatives. Molecules. 2025. doi:10.3390/molecules30153082

BibTeX
@article{deOliveira2025,
  author = {de Oliveira, Edinaldo Castro and Lara, Leonardo da Silva and Orlando, Lorraine Martins Rocha and Lanera, Sarah da Costa and de Souza, Thamyris Perez and Figueiredo, Nathalia da Silva and Paes, Vitoria Barbosa and Mazzochi, Ana Carolina and Fernandes, Pedro Henrique Myra and Dos Santos, Maurício Silva and Pereira, Mirian Claudia de Souza},
  title = {Anti-Trypanosoma cruzi Potential of New Pyrazole-Imidazoline Derivatives},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30153082}
}
Kostenlos starten →